iShares美国制药业ETF IHE 深 沪
等待开盘 04-01 09:30:00 美东时间
86.68
+2.480
+2.95%
华盛通- 最 高86.68
- 今 开84.98
- 成交量 3.39万股
- 最 低 84.98
- 昨 收 84.20
- 总市值 10.05亿
- 52周最高 92.0105
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 60.1513
- 委 比 -42.86%
- 总股本 1160.00万
- 历史最高 92.0105
- 量 比 0.63
- 振 幅 2.02%
- 历史最低 27.8371
- 每 手 1
- 风险率 9.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
01-29 01:07
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
01-16 15:30
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
2025-12-20 04:17
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
2025-11-25 01:06
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
2025-11-15 22:31
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
2025-10-31 04:04
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
2025-09-30 00:06
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
2025-09-29 15:20
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
2025-09-08 13:49
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
2025-07-26 20:31
